Cite
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2020;2(2):125-134doi: 10.1158/2643-3230.bcd-20-0143.
Alotaibi, A. S., Yilmaz, M., Kanagal-Shamanna, R., Loghavi, S., Kadia, T. M., DiNardo, C. D., Borthakur, G., Konopleva, M., Pierce, S. A., Wang, S. A., Tang, G., Guerra, V., Samra, B., Pemmaraju, N., Jabbour, E., Short, N. J., Issa, G. C., Ohanian, M., Garcia-Manero, G., Bhalla, K. N., Patel, K. P., Takahashi, K., Andreeff, M., Cortes, J. E., Kantarjian, H. M., Ravandi, F., & Daver, N. (2021). Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood cancer discovery, 2(2), 125-134. https://doi.org/10.1158/2643-3230.bcd-20-0143
Alotaibi, Ahmad S, et al. "Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors." Blood cancer discovery vol. 2,2 (2021): 125-134. doi: https://doi.org/10.1158/2643-3230.bcd-20-0143
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 Mar;2(2):125-134. doi: 10.1158/2643-3230.bcd-20-0143. Epub 2020 Dec 06. PMID: 33681815; PMCID: PMC7935111.
Copy
Download .nbib